Last reviewed · How we verify
SUGAR, INVERT
SUGAR, INVERT is a marketed product with a key composition patent expiring in 2028. The drug's market position and specific indications are not detailed, but its patent protection provides a competitive advantage until expiry. The primary risk is the potential for increased competition post-2028, which could impact market share and revenue.
At a glance
| Generic name | SUGAR, INVERT |
|---|---|
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Intestinal Microbiota Manipulation to Treat Resistant Hypertension (NA)
- Acute Medium Chain Triglycerides (MCT) Intake in Young and Older Participants (NA)
- Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer (PHASE2)
- High-dose ICE With Amifostine (PHASE2)
- Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients (NA)
- Effects of Berry Nectars Sweetened With Inverted Sugar on Post-meal Blood Sugar (NA)
- MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma (NA)
- Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SUGAR, INVERT CI brief — competitive landscape report
- SUGAR, INVERT updates RSS · CI watch RSS